RecruitingNCT06409845

Effectiveness and Tolerability of Eptinezumab

Effectiveness and Tolerability of Eptinezumab: a Prospective, Multicentric, Cohort Study

Sponsor

University of Florence

Enrollment

100 participants

Start Date

Mar 26, 2024

Study Type

OBSERVATIONAL

Conditions

Migraine with aura Migraine Chronic Migraine Migraine Without Aura

Summary

The purpose of this prospective and multicentric study is to evaluate the effectiveness and tolerability of eptinezumab as preventive migraine treatment in a cohort of episodic or chronic migraine patients.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Eptinezumab 100 or 300 mg ev for people with chronic migraine, migraine, and other related conditions. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.